ASP Isotopes (NASDAQ:ASPI) Trading Up 8.2% – Still a Buy?

ASP Isotopes Inc. (NASDAQ:ASPI)’s share price was up 8.2% during mid-day trading on Thursday . The company traded as high as $9.56 and last traded at $9.65. Approximately 1,653,990 shares traded hands during trading, a decline of 59% from the average daily volume of 4,053,896 shares. The stock had previously closed at $8.91.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on ASPI shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ASP Isotopes in a research note on Wednesday, October 8th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $11.00 price target on shares of ASP Isotopes in a research note on Wednesday, September 17th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $11.00.

ASP Isotopes Price Performance

The company has a debt-to-equity ratio of 3.53, a current ratio of 14.72 and a quick ratio of 14.56. The firm has a market cap of $917.29 million, a P/E ratio of -16.10 and a beta of 3.29. The stock’s 50-day simple moving average is $9.69 and its two-hundred day simple moving average is $8.33.

ASP Isotopes (NASDAQ:ASPI) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($1.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.92). ASP Isotopes had a negative net margin of 2,181.62% and a negative return on equity of 239.22%. The firm had revenue of $1.20 million for the quarter, compared to the consensus estimate of $1.60 million. Equities research analysts forecast that ASP Isotopes Inc. will post -0.24 earnings per share for the current fiscal year.

Insider Buying and Selling at ASP Isotopes

In other news, CEO Paul Elliot Mann sold 81,077 shares of the business’s stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $8.39, for a total transaction of $680,236.03. Following the completion of the sale, the chief executive officer directly owned 8,084,191 shares of the company’s stock, valued at approximately $67,826,362.49. The trade was a 0.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Duncan Moore sold 75,000 shares of the business’s stock in a transaction on Friday, August 29th. The shares were sold at an average price of $9.28, for a total transaction of $696,000.00. Following the sale, the director directly owned 994,553 shares of the company’s stock, valued at $9,229,451.84. This represents a 7.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 406,199 shares of company stock valued at $3,718,977. Insiders own 21.40% of the company’s stock.

Institutional Trading of ASP Isotopes

A number of large investors have recently made changes to their positions in ASPI. Ameritas Investment Partners Inc. boosted its stake in shares of ASP Isotopes by 41.2% during the second quarter. Ameritas Investment Partners Inc. now owns 5,483 shares of the company’s stock valued at $40,000 after purchasing an additional 1,600 shares during the period. BNP Paribas Financial Markets lifted its stake in ASP Isotopes by 84.9% in the second quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock worth $41,000 after acquiring an additional 2,548 shares during the period. SBI Securities Co. Ltd. lifted its stake in ASP Isotopes by 84.8% in the first quarter. SBI Securities Co. Ltd. now owns 9,370 shares of the company’s stock worth $44,000 after acquiring an additional 4,299 shares during the period. Tower Research Capital LLC TRC lifted its stake in ASP Isotopes by 96.7% in the second quarter. Tower Research Capital LLC TRC now owns 10,890 shares of the company’s stock worth $80,000 after acquiring an additional 5,353 shares during the period. Finally, PFG Investments LLC purchased a new stake in ASP Isotopes in the first quarter worth about $94,000. 16.80% of the stock is owned by hedge funds and other institutional investors.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.